LYFE Capital is a life science investment firm.
In our inaugural fund, we are only seeking biotechnology, pharmaceutical, medical device, diagnostic, healthcare service and digital health companies with an established product foundation but need a bit more capital to accelerate its growth in Greater China. During this critical time, we work closely with our portfolio companies and support their needs not only by providing capital but with market planning, talent acquisition, global expansion and global partnership support.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
May 9, 2022
Aspen Neuroscience
|
Series B | $147.50M | Biotechnology | Yes |
Mar 14, 2022
Medilink Therapeutics
|
Series B | $70M | Biotechnology | Yes |
Feb 9, 2021
Cleveland Diagnostics
|
Series D | $17.40M | Biotechnology | Yes |